Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fluid overload hides true lung pressure in dialysis patients, study aims to unmask it

NCT ID NCT07676786

Knowledge-focused Sponsor: Stefan Lujinschi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study looks at why people with end-stage kidney disease on dialysis often develop high blood pressure in the lungs (pulmonary hypertension). Fluid buildup can make this condition seem worse than it is. Researchers will first correct fluid levels, then use heart ultrasound and, if needed, a catheter to measure lung pressures accurately. The goal is to find the true rate and types of pulmonary hypertension in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could improve how doctors diagnose and classify pulmonary hypertension in dialysis patients, leading to more accurate treatment.
What could go wrong
This is a small observational study, so findings may not apply to all patients. It does not test a new treatment, so direct patient benefits are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with end-stage kidney disease (ESKD) receiving maintenance hemodialysis in two tertiary referral centers. Participants are consecutively enrolled and undergo structured volume assessment and optimization. The primary analysis includes patients who achieve predefined euvolemia criteria.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * End-stage kidney disease on maintenance HD for ≥ 3 months. * Stable clinical condition (no hospitalization in last 30 days). * Able and willing to comply with study protocol. * Provision of written informed consent Exclusion Criteria: * Moderate/severe left-sided valvular disease. * Active pulmonary or cardiac decompensation. * Persistent hypervolemia after completion of the volume assessment and correction phase * Inability to undergo echocardiography or bioimpedance assessment. * Acute infection or inflammatory condition at the time of enrollment. * Inadequate echocardiographic window preventing reliable assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage kidney disease (ESRD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease Edema end stage renal failure pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage kidney disease (ESRD) Hemodialysis Hemodialysis patients Pulmonary hypertension (PH) Volume assessment Volume overload

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fundeni Clinical Institute

    Bucharest, 022328, Romania

  • Institute for Cardiovascular Diseases C.C. Iliescu

    Bucharest, 022322, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.